Surmodics, Inc. (SRDX, Financial) has announced the publication of significant results from its TRANSCEND clinical trial. This study, which is global and randomized in nature, has demonstrated that the SurVeil drug-coated balloon (DCB) is comparable in safety and efficacy to the IN.Pact Admiral DCB when treating patients with femoropopliteal arterial disease. Notably, SurVeil achieves these outcomes while utilizing a considerably lower dose of medication.
The details of this trial have been documented in the March issue of the European Journal of Vascular and Endovascular Surgery. The findings provide essential insights into treatment options for patients suffering from this type of arterial disease, potentially marking a significant advancement in vascular intervention with more efficient drug usage.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Surmodics Inc (SRDX, Financial) is $43.00 with a high estimate of $43.00 and a low estimate of $43.00. The average target implies an upside of 50.61% from the current price of $28.55. More detailed estimate data can be found on the Surmodics Inc (SRDX) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Surmodics Inc's (SRDX, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Surmodics Inc (SRDX, Financial) in one year is $37.18, suggesting a upside of 30.23% from the current price of $28.55. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Surmodics Inc (SRDX) Summary page.
